Mesoblast Limited American Depositary Shares
MESO Real Time Price USDRecent trades of MESO by members of U.S. Congress
No Congress Trading data for this ticker
Congress Trading Dashboard
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
---|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
---|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
---|
Recently reported changes by institutional investors
Quarterly net insider trading by MESO's directors and management
No recent Insider Trading for this ticker
Insider Trading DashboardGovernment lobbying spending instances
No Corporate Lobbying instances for this ticker
Corporate Lobbying DashboardEstimated quarterly lobbying spending
No Corporate Lobbying data for this ticker
Corporate Lobbying DashboardNew patents grants
-
Patent Title: Methods for increasing osteoblastic function Oct. 05, 2021
-
Patent Title: Method of treating graft versus host disease Dec. 01, 2020
-
Patent Title: Methods of treating or preventing respiratory conditions Jun. 23, 2020
-
Patent Title: Methods of treating or preventing rheumatic disease Mar. 24, 2020
-
Patent Title: Method of increasing proliferation of bone marrow mononuclear cells expressing stro1- Jan. 28, 2020
-
Patent Title: Perivascular mesenchymal precursor cells Sep. 24, 2019
-
Patent Title: Mesenchymal precursor cell Mar. 05, 2019
-
Patent Title: Methods of treating multiple sclerosis using stro-1+ and tnap+ multipotential cells Feb. 19, 2019
-
Patent Title: Methods for treating obesity and/or metabolic syndrome Dec. 25, 2018
-
Patent Title: Method of treating graft versus host disease Oct. 23, 2018
-
Patent Title: Methods of treating or preventing respiratory conditions Jul. 24, 2018
-
Patent Title: Methods of treating or preventing rheumatic disease May. 22, 2018
-
Patent Title: Method for treating or preventing a pancreatic dysfunction May. 15, 2018
-
Patent Title: Methods for increasing osteoblastic function May. 09, 2017
-
Patent Title: Production of reprogrammed pluripotent cells Nov. 08, 2016
-
Patent Title: Method for treating diabetic renal failure or syndrome x Nov. 01, 2016
-
Patent Title: Expansion of haemopoietic precursors Aug. 16, 2016
-
Patent Title: Methods for treating obesity and/or metabolic syndrome Jul. 12, 2016
-
Patent Title: Methods of generating, repairing and/or maintaining connective tissue in vivo Jul. 05, 2016
-
Patent Title: Method of treating graft versus host disease Apr. 05, 2016
-
Patent Title: Methods of treating or preventing rheumatic disease Feb. 23, 2016
-
Patent Title: Perivascular mesenchymal precursor cell induced blood vessel formation Nov. 03, 2015
-
Patent Title: Perivascular mesenchymal precursor cell induced blood vessel formation Oct. 27, 2015
-
Patent Title: Monoclonal antibody stro-4 Jul. 28, 2015
-
Patent Title: Method for treating or preventing a pancreatic dysfunction Nov. 25, 2014
-
Patent Title: Repair and/or reconstitution of invertebral discs Oct. 14, 2014
-
Patent Title: Expansion of haemopoietic precursors Sep. 09, 2014
-
Patent Title: Isolation of adult multipotential cells by tissue non-specific alkaline phosphatase Feb. 05, 2013
Federal grants, loans, and purchases
No Government Contracts for this ticker
Government Contracts DashboardEstimated quarterly amount awarded from public contracts
Number of mentions of MESO in WallStreetBets Daily Discussion
Recent insights relating to MESO
Recent picks made for MESO stock on CNBC
ETFs with the largest estimated holdings in MESO
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view MESO Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.